Eremanthin is a natural compound isolated from the roots of the plant *Eremophila mitchellii*. It has been shown to have potential anti-inflammatory and antioxidant properties. Its biosynthesis is thought to involve the shikimate pathway, leading to the production of a phenylpropanoid precursor. Further studies are investigating its potential as a therapeutic agent for conditions such as arthritis and neurodegenerative diseases. The unique structure and biological activities of eremanthin make it a subject of ongoing research.'
| ID Source | ID |
|---|---|
| PubMed CID | 100572 |
| CHEMBL ID | 451364 |
| CHEBI ID | 4815 |
| SCHEMBL ID | 9516039 |
| MeSH ID | M0043271 |
| Synonym |
|---|
| NCI60_002782 |
| azuleno[4, 3a,4,6a,7,8,9,9a,9b-octahydro-6-methyl-3,9-bis(methylene)-, [3as-(3a.alpha.,6a.alpha.,9a.alpha.,9b.beta.)]- |
| nsc-321215 |
| NSC321215 , |
| C09406 |
| eremanthin |
| 37936-58-6 |
| (3as,6ar,9ar,9bs)-6-methyl-3,9-dimethylidene-4,6a,7,8,9a,9b-hexahydro-3ah-azuleno[4,5-b]furan-2-one |
| chebi:4815 , |
| CHEMBL451364 |
| nsc 321215 |
| azuleno(4,5-b)furan-2(3h)-one, 3a,4,6a,7,8,9,9a,9b-octahydro-6-methyl-3,9-bis(methylene)-, (3as-(3aalpha,6aalpha,9aalpha,9bbeta))- |
| SCHEMBL9516039 |
| DTXSID50191371 |
| Q27106489 |
Eremanthin is a potent anticancer agent against human cervical cancer. It may be included as lead molecule in cervical cancer treatment provided further in vitro and in vivo investigations are performed.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Eremanthin molecule is a potent anticancer agent against human cervical cancer and may be included as lead molecule in cervical cancer treatment provided further in vitro and in vivo investigations are performed." | ( Anticancer activity of Eremanthin against the human cervical cancer cells is due to G2/M phase cell cycle arrest, ROS-mediated necrosis-like cell death and inhibition of PI3K/AKT signalling pathway. Kong, W; Liu, T; Liu, Y; Song, D; Zhao, X, ) | 1.88 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Eremanthin treatment led to G2/M-phase cell cycle arrest." | ( Anticancer activity of Eremanthin against the human cervical cancer cells is due to G2/M phase cell cycle arrest, ROS-mediated necrosis-like cell death and inhibition of PI3K/AKT signalling pathway. Kong, W; Liu, T; Liu, Y; Song, D; Zhao, X, ) | 1.16 |
| Class | Description |
|---|---|
| sesquiterpene lactone | Any member of a diverse class of complex, multicyclic phytochemicals showing a variety of skeleton arrangements and bioactivities, and having in common a sesquiterpenoid structure including a lactone ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID377924 | Inhibition of killing activity of CD8+ specific mouse CTL-OE4 cells | 1999 | Journal of natural products, Jan, Volume: 62, Issue:1 | Guaianolides as immunomodulators. Synthesis and biological activities of dehydrocostus lactone, mokko lactone, eremanthin, and their derivatives. |
| AID377925 | Inhibition of IL-1-beta-induced ICAM1 expression in human A549 cells | 1999 | Journal of natural products, Jan, Volume: 62, Issue:1 | Guaianolides as immunomodulators. Synthesis and biological activities of dehydrocostus lactone, mokko lactone, eremanthin, and their derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||